Miach Orthopaedics

OverviewSuggest Edit

Miach Orthopaedics is a company developing bio-engineered surgical implants for connective tissue repair. Its initial focus is on the Bridge-Enhanced ACL Repair (BEAR) technology as a viable alternative to conventional ACL reconstruction for patients who have sustained an anterior cruciate ligament (ACL) injury.

Latest Updates

Employees (est.) (Jun 2022)30(-6%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Miach Orthopaedics

Martha Shadan

Martha Shadan

President & Chief Executive Officer
Michael McNulty

Michael McNulty

Vice President of Sales & Marketing
Michael O'Hara

Michael O'Hara

Vice President of Quality Assurance
Rita Paparazzo

Rita Paparazzo

Vice President of Clinical Operations
Stephen Wohlert

Stephen Wohlert

Vice President of Manufacturing
Martha Murray

Martha Murray

Show more

Miach Orthopaedics Financials and Metrics

Summary Metrics

Founding Date


Miach Orthopaedics total Funding

$22.5 m

Miach Orthopaedics latest funding size

$22.5 m

Time since last funding

4 years ago

Miach Orthopaedics investors

Miach Orthopaedics's latest funding round in September 2018 was reported to be $22.5 m. In total, Miach Orthopaedics has raised $22.5 m
Show all financial metrics

Miach Orthopaedics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Miach Orthopaedics Online and Social Media Presence

Embed Graph

Miach Orthopaedics Frequently Asked Questions

  • When was Miach Orthopaedics founded?

    Miach Orthopaedics was founded in 2016.

  • Who are Miach Orthopaedics key executives?

    Miach Orthopaedics's key executives are Martha Shadan, Michael McNulty and Michael O'Hara.

  • How many employees does Miach Orthopaedics have?

    Miach Orthopaedics has 30 employees.

  • Who are Miach Orthopaedics competitors?

    Competitors of Miach Orthopaedics include fasciotens, KitoTech Medical and Intrinsic Therapeutics.